ライフサイエンスコーパス: oxycodone

1 and it may enhance the analgesic effects of oxycodone.

2 s used to measure the reinforcing effects of oxycodone.

3 ulate the rewarding and analgesic actions of oxycodone.

4 ted pain plus a prescription for morphine or oxycodone.

5 ant during specific time periods, especially oxycodone.

6 commonly prescribed opioids were codeine and oxycodone.

7 oid-treated patients received codeine and/or oxycodone.

8 lion g), fentanyl (1168%; 3263 to 41,371 g), oxycodone (23%; 1.6 to 2.0 million g), and hydromorphone

9 decreased for meperidine (39%; 1335 to 806), oxycodone (29%; 4526 to 3190), fentanyl (59%; 59 to 24),

10 XN PR or placebo for 16 weeks (starting dose oxycodone 5 mg, naloxone 2.5 mg, twice daily).

11 ablets of placebo; cyclobenzaprine, 5 mg; or oxycodone, 5 mg/acetaminophen, 325 mg.

12 ogen (6OXY(Gly)(4)-KLH) for the treatment of oxycodone abuse.

13 obenzaprine group 19 (IQR,17-21), and in the oxycodone/acetaminophen group 20 (IQR,17-22).

14 n the cyclobenzaprine group, and 11.1 in the oxycodone/acetaminophen group.

15 senting to the ED, adding cyclobenzaprine or oxycodone/acetaminophen to naproxen alone did not improv

16 .3 (98.3% CI, -1.5 to 4.1; P = .28), and for oxycodone/acetaminophen vs cyclobenzaprine, 0.9 (98.3% C

17 as 0.3 (98.3% CI, -2.6 to 3.2; P = .77), for oxycodone/acetaminophen vs placebo, 1.3 (98.3% CI, -1.5

18 acebo and 108 each to cyclobenzaprine and to oxycodone/acetaminophen.

19 hoice sessions were completed involving oral oxycodone administration (0, 15, and 30 mg/70 kg, p.o.).

20 he role of RGS9-2 in regulating responses to oxycodone, an MOR agonist prescribed for the treatment o

21 profen and 1000 mg of acetaminophen; 5 mg of oxycodone and 325 mg of acetaminophen; 5 mg of hydrocodo

22 ore from baseline to 2 hours was between the oxycodone and acetaminophen group and the hydrocodone an

23 en group; by 4.4 (95% CI, 3.7 to 5.0) in the oxycodone and acetaminophen group; by 3.5 (95% CI, 2.9 t

24 plume for nonresonant laser vaporization of oxycodone and atenolol desorbed from steel is 2.4% +/- 1

25 Subjective effects of oxycodone and drug craving were measured with visual ana

26 enerate immunogens that would recognize both oxycodone and hydrocodone.

27 ion to brain, and blunted analgesia for both oxycodone and hydrocodone.

28 Other drugs such as oxycodone and noroxycodone lose water in a single-stage

29 Thus Michael reaction of the benzylimines of oxycodones and oxymorphones with nitrostyrenes gave a se

30 ent required supplemental narcotics (5 mg of oxycodone) and sedatives (1 mg lorezapam), and one patie

31 of the pharmaceutical compounds loratadine, oxycodone, and atenolol deposited on glass, wood, steel,

32 tance, followed by alcohol, opiate, cocaine, oxycodone, and methamphetamine.

33 paracetamol, codeine, co-dydramol, tramadol, oxycodone, and morphine) during 2005-2010 compared with

34 Is oxycodone associated with greater efficacy and fewer adv

35 In this study, oxycodone-based and hydrocodone-based haptens were conju

36 polyclonal B cell population specific for an oxycodone-based hapten (6OXY) was analyzed by flow cytom

37 a mixture of morphine, codeine, oxymorphone, oxycodone, clozapine, and buspirone and their deuterated

38 placebo ibudilast condition under the 15 mg oxycodone condition, but not significantly lower under t

39 but not significantly lower under the 30 mg oxycodone condition.

40 gle in vivo exposure to the opioid analgesic oxycodone disrupted mu OP-LTD and endocannabinoid-LTD, b

41 rum Ab titers and their efficacy in blocking oxycodone distribution to the brain and oxycodone-induce

42 remained slight during the study, with mean oxycodone doses of 114 mg/d (range, 20 to 400 mg/d) for

43 oderate to severe pain were randomized to CR oxycodone every 12 hours (n=81) or IR oxycodone four tim

44 CR oxycodone every 12 hours was as effective as IR oxycodon

45 ng, using intravenous self-administration of oxycodone, fentanyl, and buprenorphine in rats allowed l

46 We found that animals that self-administered oxycodone, fentanyl, or heroin, but not buprenorphine ha

47 to CR oxycodone every 12 hours (n=81) or IR oxycodone four times daily (n=83) for 5 days in a multic

48 codone every 12 hours was as effective as IR oxycodone four times daily in managing moderate to sever

49 An oxycodone hapten containing a tetraglycine linker at the

50 This study compared the clinical efficacy of oxycodone hydrochloride controlled-release (CR) tablets

51 o reduce wide-scale abuse of the proprietary oxycodone hydrochloride formulation OxyContin, an abuse-

52 r representative opioids (morphine, codeine, oxycodone, hydrocodone) and five stimulants (amphetamine

53 tions of six prescription opioid analgesics: oxycodone, hydrocodone, hydromorphone, fentanyl, morphin

54 other abused opioids, including hydrocodone, oxycodone, hydromorphone, oxymorphone, and codeine.

55 ving), reinforcing, and analgesic effects of oxycodone in human volunteers diagnosed with opioid depe

56 ositively regulates the rewarding effects of oxycodone in pain-free states, and in a model of neuropa

57 Desirable high cross-reactivity to oxycodone, in addition to other common opiates, morphine

58 king oxycodone distribution to the brain and oxycodone-induced behavior in mice.

59 ose-dependently inhibited the acquisition of oxycodone-induced conditioned place preference (CPP) in

60 Compound 19 inhibited oxycodone-induced hyperlocomotion in mice and reduced ox

61 -induced hyperlocomotion in mice and reduced oxycodone-induced locomotor sensitization.

62 codynamics, since TLR4(-/-) mice had reduced oxycodone-induced p38 and JNK phosphorylation, while dis

63 ine > fentanyl = oxymorphine > butorphanol = oxycodone = nalbuphine.

64 the analgesic efficacy of prolonged-release oxycodone-naloxone (OXN PR) in patients with Parkinson's

65 Tapentadol and oxycodone-naloxone are found to exhibit better tolerabil

66 Tapentadol was followed by oxycodone-naloxone combination in providing better toler

67 ent satisfaction was found to be higher with oxycodone-naloxone followed by fentanyl and tapentadol.

68 -2 does not affect the analgesic efficacy of oxycodone or the expression of physical withdrawal, it o

69 each year, in 2010 usually for hydrocodone, oxycodone, or tramadol.

70 effects than patients with CKD who received oxycodone (P = .010).

71 re reported with CR (109) than with IR (186) oxycodone (P=.006).

72 other analgesics, apart from an increase in oxycodone poisonings, but numbers were small.

73 u-opioids including fentanyl, methadone, and oxycodone produced acute analgesic tolerance that was bl

74 Medications prescribed were codeine, oxycodone, propoxyphene, tramadol, morphine, meperidine,

75 ssful detection of a commonly abused opiate, oxycodone, resulted in 100% qualitative agreement betwee

76 ted the analgesic actions of hydrocodone and oxycodone, shifting their ED(50) values by 2.5-fold and

77 munization, correlated to subsequent greater oxycodone-specific serum Ab titers and their efficacy in

78 MS imaging of the spatial distribution of an oxycodone spot on a metal slide with resolution of 250 m

79 d every 12 hours with immediate-release (IR) oxycodone tablets administered four times daily in patie

80 1% lower odds of receiving a prescription of oxycodone than white patients (P < .001).

81 gainst the highly abused prescription opioid oxycodone, the polyclonal B cell population specific for

82 al withdrawal, it opposes the development of oxycodone tolerance, in both acute pain and chronic neur

83 nt of rheumatic disease pain with codeine or oxycodone was effective in reducing pain severity and wa

84 without evidence for internalization; and 3) oxycodone was ineffective in both processes.

85 Oxycodone was not associated with superior cancer pain r

86 n, ratings of drug liking following 15 mg of oxycodone were decreased significantly.